8 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Mar 24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
4:05pm
messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
26 Sep 23
Entry into a Material Definitive Agreement
4:06pm
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
14 Aug 23
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
12:00am
be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Aug 23
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
4:23pm
RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying mRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered
8-K
EX-99.1
0ibhs5as2j8 sajbgk8
13 Dec 22
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
4:14pm
8-K
EX-99.1
p6r3xnbkwk5q902xwvjf
9 Nov 22
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
4:06pm
8-K
EX-99.1
1pw2m2clcufixfj3t7kg
9 May 22
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
4:20pm
- Prev
- 1
- Next